[Chemoembolization of the hepatic artery in the treatment of primary and metastatic liver cancer].
The results of hepatic arterial chemoembolization (HACE) with the liposoluble cytostatic Dioxadet were analysed in 200 patients. HACE was performed for palliative therapy for nonresectable liver cancer in 150 patients ans as neo- or adjuvant therapy in addition to hepatic resection in 50 patients. The oily chemoembolizate was injected into the portal vein along with HACE in 50 patients. The results have shown that HACE, particularly in combination with intra-portal chemoembolization is an effective palliative treatment for nonresectable malignant liver tumors, by increasing survival rates at least in half the patients. Pre- and postoperative chemoembolization reduces the number of relapses after resection of liver neoplasms.